unum therapeutics is a cambridge, massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. unum has built an antibody-coupled t-cell receptor (actr) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic t-lymphocytes (ctls) to kill tumor cells. in contrast to other approaches that hit a single target and treat a narrow set of tumors, unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. unum’s vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. unum's lead program based on actr technology is currently in phase i clinical testing to assess safety and efficacy in certain forms of leukemia and lymphoma. in parallel, unum is act
Company profile
Ticker
COGT
Exchange
Website
CEO
Andrew R. Robbins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Unum Therapeutics Inc., Unum Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Mono Inc. • Kiq Bio LLC ...
COGT stock data
Latest filings (excl ownership)
8-K
Unregistered Sales of Equity Securities
22 Mar 24
S-8
Registration of securities for employees
26 Feb 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
26 Feb 24
8-K
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
14 Feb 24
8-K
Other Events
11 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
2 Nov 23
S-8
Registration of securities for employees
8 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
Latest ownership filings
SC 13D/A
Fairmount Funds Management LLC
27 Mar 24
SC 13D/A
Fairmount Funds Management LLC
16 Feb 24
4
Change in insider ownership
16 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G
Kynam Capital Management, LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
TCG Crossover GP I, LLC
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 86.81 mm | 86.81 mm | 86.81 mm | 86.81 mm | 86.81 mm | 86.81 mm |
Cash burn (monthly) | 42.50 mm | 4.58 mm | 19.86 mm | 16.14 mm | 12.66 mm | 11.58 mm |
Cash used (since last report) | 254.23 mm | 27.42 mm | 118.79 mm | 96.52 mm | 75.71 mm | 69.27 mm |
Cash remaining | -167.42 mm | 59.39 mm | -31.98 mm | -9.71 mm | 11.10 mm | 17.54 mm |
Runway (months of cash) | -3.9 | 13.0 | -1.6 | -0.6 | 0.9 | 1.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 143 |
Opened positions | 12 |
Closed positions | 13 |
Increased positions | 58 |
Reduced positions | 36 |
13F shares | Current |
---|---|
Total value | 883.17 bn |
Total shares | 112.19 mm |
Total puts | 20.00 k |
Total calls | 36.60 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Venrock Healthcare Capital Partners II | 7.31 mm | $0.00 |
Ra Capital Management | 6.42 mm | $62.56 bn |
BLK Blackrock | 6.15 mm | $59.93 bn |
TCG Crossover Management | 5.63 mm | $54.90 bn |
Commodore Capital | 5.57 mm | $54.27 bn |
VR Adviser | 4.68 mm | $45.67 bn |
FMR | 4.57 mm | $44.56 bn |
Vanguard | 4.37 mm | $42.64 bn |
Point72 Asset Management | 3.77 mm | $36.73 bn |
TCG Crossover GP I | 3.63 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Feb 24 | Fairmount Funds Management | Common Stock | Grant | Acquire A | Yes | No | 7.5 | 1,166,666 | 8.75 mm | 4,438,790 |
16 Feb 24 | Fairmount Funds Management | Series B Convertible Preferred Stock Common Stock | Grant | Acquire A | Yes | No | 7500 | 1,500 | 11.25 mm | 1,500 |
23 Jan 24 | Green John L. | Stock Option Common Stock | Grant | Acquire A | No | No | 4.63 | 300,000 | 1.39 mm | 300,000 |
23 Jan 24 | Jessica Sachs | Stock Option Common Stock | Grant | Acquire A | No | No | 4.63 | 300,000 | 1.39 mm | 300,000 |
23 Jan 24 | Robbins Andrew R | Stock Option Common Stock | Grant | Acquire A | No | No | 4.63 | 1,100,000 | 5.09 mm | 1,100,000 |
23 Jan 24 | Evan Kearns | Stock Option Common Stock | Grant | Acquire A | No | No | 4.63 | 255,000 | 1.18 mm | 255,000 |
News
JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $20
27 Feb 24
Citigroup Maintains Buy on Cogent Biosciences, Raises Price Target to $13
26 Feb 24
Cogent Biosciences Q4 EPS $(0.63) Down From $(0.56) YoY
26 Feb 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
26 Feb 24
Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target
26 Feb 24
Press releases
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
26 Feb 24
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
22 Feb 24
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
14 Feb 24
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
2 Jan 24